Clinical Trials Directory

Trials / Completed

CompletedNCT05739656

Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ET

A PROSPECTIVE, MULTICENTER, POST-MARKET OBSERVATIONAL STUDY TO EVALUATE ROTATIONAL STABILITY AND FUNCTIONAL VISUAL ACUITY OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TORIC IOL MX60ET FOLLOWING CATARACT SURGERY PROTOCOL.

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Bausch & Lomb Incorporated · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to evaluate rotational stability and functional improvements in visual acuity of the enVista monofocal Toric IOL (MX60ET) following cataract surgery.

Detailed description

This is a prospective, multicenter, post-market observational study at approximately 5 sites in the United States. All clinical sites will have Institutional Review Board (IRB) approval prior to recruiting potential subjects. All subjects who meet eligibility criteria will be consecutively offered enrollment into the trial. Approximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes at up to 5 clinical sites in the United States. For subjects with pre-existing cataracts in both eyes requiring removal and IOL implantation, the eye with the worse BCDVA at the preoperative visit will be designated the study eye. If BCDVA is the same for both eyes, the right eye will be designated the study eye. Postoperatively, all subjects will undergo ophthalmic examinations at regular intervals per the study visit schedule through Form 4 (120-180 days postoperative).

Conditions

Interventions

TypeNameDescription
PROCEDURECATARACT SURGERYApproximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes.

Timeline

Start date
2020-08-01
Primary completion
2022-07-06
Completion
2022-07-06
First posted
2023-02-22
Last updated
2023-02-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05739656. Inclusion in this directory is not an endorsement.